Systems biology of Ebola virus and Lassa virus determinants of infection outcome
Systems biology of Ebola virus and Lassa virus determinants of infection outcome
批准号:
10374720
负责人:
Kristian Graugaard Andersen
金额:
$42.5万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-02-01 至 2023-01-31
关键词:
Adaptive Immune SystemAffectAfricaAnimal ModelAntibodiesAreaCase Fatality RatesCatalogsCellsClinicalCommunicable DiseasesComplementComputer ModelsContainmentDataData SetDevelopmentDiseaseDisease OutcomeEbolaEbola Hemorrhagic FeverEbola virusEpitopesFutureGenerationsGeneticGenotypeGlycoproteinsGoalsHumanImmuneImmune EvasionIndividualInfectionIntegration Host FactorsInvestigationLassa FeverLassa virusLeadLinkMissionModelingMolecularMutationOutcomePatientsPersonsPlayProcessRiskRodentRoleSeroprevalencesSeveritiesSeverity of illnessSuggestionSurvivorsSystemSystems BiologyTechnologyTestingTherapeuticViralViral Hemorrhagic FeversVirusVirus Diseasesantibody engineeringassociated symptombaseco-infectioncohortcostdeep sequencingexperimental studyfitnessgenomic datahuman diseasehuman pathogeninsightpathogenpredictive markerpredictive modelingtechnological innovationtransmission processviral genomicsvirus genetics
中文摘要
项目概要/摘要
拉沙病毒和埃博拉病毒是两种最具破坏性的人类病原体,
导致严重出血热,病死率超过70%。 据估计,
每年有数千人死于拉沙热尽管住院埃博拉的病死率很高,
和拉沙热患者,已经确定无症状或轻度症状的感染发生在
拉沙热和埃博拉病毒 我们知道病毒遗传学在决定疾病严重程度方面起着关键作用,
然而,缺乏对机制的了解,也没有进行系统的研究来鉴定病毒,
人类疾病的相关因素。同样,拉沙热和埃博拉幸存者中有很高比例的人
与疾病相关的长期症状,但可能决定这些并发症的病毒因素
仍然难以捉摸
该项目的核心假设是,拉沙和埃博拉病毒中的特定遗传因子对人类的免疫力至关重要。
感染的结果。 直接与独特的拉沙和埃博拉患者和幸存者群体合作,
西非,我们将确定拉沙病毒和埃博拉病毒的因素,是人类疾病的决定因素。我们
将整合高通量的“组学”方法,高遏制实验,和计算
建模以阐明决定传染病严重程度的分子网络。基于这些发现,
我们将建立可用于确定拉沙病毒和埃博拉病毒感染风险的预测模型。
我们将通过完成三个总体目标来实现这些目标。 在具体目标1中,我们将创建和
分析拉沙和埃博拉病毒的大规模基因组数据集,以及感染患者的基因型。我们将
深入研究病毒从自然宿主传播给人类的过程中是如何进化的
以及人类之间的关系,并确定这如何影响临床结果。 具体目标2:
以高通量方式对个体拉沙病毒和埃博拉病毒突变进行功能表征
假设其影响感染结果。最后,在具体目标3中,我们将在高
遏制,以确定拉沙病毒和埃博拉病毒中个别突变的功能效应,
研究免疫逃逸和感染的机制。作为这一目标的一部分,我们还将设计抗体,
以更好地靶向这两种病毒,这可以作为未来治疗的起点。
英文摘要
Project Summary / Abstract
Lassa virus and Ebola virus are two of the most devastating human pathogens and infection with both can
lead to severe hemorrhagic fever with case fatality rates in excess of 70%. It is estimated that tens of
thousands of people die from Lassa fever each year. Despite the high case fatality rates of hospitalized Ebola
and Lassa fever patients, it is well established that asymptomatic or mildly symptomatic infections occur in
both Lassa fever and Ebola. We know that virus genetics play key roles in determining disease severity,
however, mechanistic insights are lacking and no systematic studies have been performed to identify virus
correlates of human disease. Similarly, a high proportion of Lassa fever and Ebola survivors develop serious
long-term symptoms associated with their disease, but virus factors that may determine these complications
remain elusive.
The central hypothesis of this project, is that specific genetic factors in Lassa and Ebola viruses critically
influence infection outcomes. Working directly with unique Lassa and Ebola patient and survivor cohorts in
West Africa, we will identify Lassa virus and Ebola virus factors that are determinants of human disease. We
will integrate high-throughput ‘omics’ approaches, high-containment experimentation, and computational
modeling to elucidate molecular networks that determine infectious disease severity. Based on these findings,
we will build predictive models that can be used to determine risk from Lassa virus and Ebola virus infection.
We will achieve these goals by completing three overarching goals. In Specific Aim 1, we will create and
analyze large-scale genomic data sets of Lassa and Ebola viruses, and genotype of infected patients. We will
perform deep investigations of how the viruses evolve as they transmit from their natural reservoirs to humans
and between humans, and determine how that can affect clinical outcomes. In Specific Aim 2, we will
functionally characterize, in a high-throughput manner, individual Lassa virus and Ebola virus mutations
hypothesized to influence infectious outcomes. Finally, in Specific Aim 3 we will perform experiments in high
containment to determine functional effects of individual mutations in Lassa virus and Ebola virus, and
investigate mechanisms of immune escape and infection. As part of this aim, we will also engineer antibodies
to better target both viruses, which can be used as a starting point for future therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10653441
-
项目类别:
-
资助金额:$184.89万
-
财政年份:2022
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology (CViSB)
-
批准号:10469781
-
项目类别:
-
资助金额:$59.71万
-
财政年份:2021
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology Administrative Core
-
批准号:10469782
-
项目类别:
-
资助金额:$59.71万
-
财政年份:2021
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10440593
-
项目类别:
-
资助金额:$26.63万
-
财政年份:2021
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10631738
-
项目类别:
-
资助金额:$35.86万
-
财政年份:2020
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10910587
-
项目类别:
-
资助金额:$23.6万
-
财政年份:2020
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10394323
-
项目类别:
-
资助金额:$174.99万
-
财政年份:2020
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10842168
-
项目类别:
-
资助金额:$80.18万
-
财政年份:2020
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10616665
-
项目类别:
-
资助金额:$174.13万
-
财政年份:2020
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology (CViSB)
-
批准号:10248803
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology Administrative Core
-
批准号:10579082
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Systems biology of Ebola virus and Lassa virus determinants of infection outcome
-
批准号:10310606
-
项目类别:
-
资助金额:$11.52万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology Administrative Core
-
批准号:10310601
-
项目类别:
-
资助金额:$7.29万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Project 2
-
批准号:10558424
-
项目类别:
-
资助金额:$64.26万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology (CViSB)
-
批准号:10579081
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology (CViSB)
-
批准号:10374714
-
项目类别:
-
资助金额:$255.0万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Administrative Core
-
批准号:10558419
-
项目类别:
-
资助金额:$31.68万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology (CViSB)
-
批准号:10356250
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Systems biology of Ebola virus and Lassa virus determinants of infection outcome
-
批准号:10579087
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Center for Viral Systems Biology (CViSB)
-
批准号:10558418
-
项目类别:
-
资助金额:$265.04万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
海外基金